Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

NCT03072589 is registered in ClinicalTrials.gov with Christine Lau, MD as lead sponsor.

NCT NCT03072589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03072589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation
Lead sponsor
Christine Lau, MD
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2017
Completion date
August 1, 2022
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant